Clinical Study | Open Access
A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas
Introduction. The role of vinorelbine in specific soft tissue sarcoma subtypes is unclear. We present retrospective single institution experience with single-agent vinorelbine in subjects with metastatic soft tissue malignancies. Methods. Fifty-eight patients were treated with single agent intravenous vinorelbine between April 1997 and December 2004. Doxorubicin had been administered previously to 53 subjects (91), and the median number of lines of previous chemotherapy was 3 (range 0–7). Results. Patients received a median 6 doses of vinorelbine (range 1–65). The overall response rate was 6 (3 patients: 1 angiosarcoma, 1 epithelioid sarcoma, and 1 embryonal rhabdomyosarcoma). Fourteen patients (26) experienced a best result of stable disease. Median time to progression was 1.8 months (95 confidence intervals 1.5–2.1 months, Kaplan-Meier estimate). Eight patients experienced grade 3 or 4 toxicity, most commonly febrile neutropenia. Conclusion. Vinorelbine demonstrates limited activity in a heavily pretreated group of soft-tissue sarcoma patients. Prospective investigation may be considered for selected sarcoma subtypes.
- A Jemal, R Siegel, E Ward et al., “Cancer statistics, 2006,” CA: A Cancer Journal for Clinicians, vol. 56, no. 2, pp. 106–130, 2006.
- M F Brennan, S Singer, R G Maki, and B O'Sullivan, “Soft tissue sarcoma,” in Cancer: Principles & Practice of Oncology, V T Jr DeVita, S Hellman, and S A Rosenberg, Eds., pp. 1581–1637, Lippincott Williams & Wilkins, Philadelphia, Pa, 7th edition, 2005.
- K H Antman and A D Elias, “Chemotherapy of advanced soft-tissue sarcomas,” Seminars in Surgical Oncology, vol. 4, no. 1, pp. 53–58, 1988.
- L Svancarova, J Y Blay, I R Judson et al., “Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 38, no. 4, pp. 556–559, 2002.
- M L Hensley, R G Maki, E Venkatraman et al., “Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial,” Journal of Clinical Oncology, vol. 20, no. 12, pp. 2824–2831, 2002.
- J A Gottlieb, R S Benjamin, L H Baker et al., “Role of DTIC (NSC-45388) in the chemotherapy of sarcomas,” Cancer Treatment Reports, vol. 60, no. 2, pp. 199–203, 1976.
- M Casanova, A Ferrari, F Spreafico et al., “Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma,” Cancer, vol. 94, no. 12, pp. 3263–3268, 2002.
- G Nasti, D Errante, R Talamini et al., “Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study,” Journal of Clinical Oncology, vol. 18, no. 7, pp. 1550–1557, 2000.
- P Fidias, G Demetri, and D Harmon, “Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/Dana Farber/Partner's Cancer Care Study,” Proceedings of the American Society for Clinical Oncology, vol. 17, p. 1977, 1998.
- M Van Glabbeke, J Verweij, I Judson, and O S Nielsen, “EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas,” European Journal of Cancer, vol. 38, no. 4, pp. 543–549, 2002.
- K M Leu , L J Ostruszka, D Shewach et al., “Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1706–1712, 2004.
- J O Bay, I Ray-Coquard, J Fayette et al., “Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis,” International Journal of Cancer, vol. 119, no. 3, pp. 706–711, 2006.
- R G Maki, M L Hensley, J K Wathen et al., “A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS),” Journal of Clinical Oncology, vol. 24, no. 18S, p. 9514, 2006.
- F Grosso, G D Demetri, J-Y Blay et al., “Patterns of tumor response to trabectedin (ET-743) in myxoid liposarcomas,” Journal of Clinical Oncology, vol. 24, no. 18S, p. 9511, 2006.
Copyright © 2006 Sibyl E. Anderson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.